AGGRASTAT® (tirofiban HCl)

Updated Indication

AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Recommended Dosing Regimen

NEW AGGRASTAT High-Dose Bolus (HDB): Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance ≤60 mL/min, give 25 mcg/kg over 5 minutes and then 0.075 mcg/kg/min.

In clinical studies using the HDB regimen, AGGRASTAT was administered in combination with aspirin, clopidogrel and heparin or bivalirudin to over 8,000 patients for typically ≤24 hours.1

Platelet Aggregation Inhibition

The HDB regimen achieves >90% inhibition of platelet aggregation within 10 minutes of bolus administration.2

Platelet Inhibition

AGGRASTAT Receives a Class I Recommendation in the following Guidelines:

  • ACC/AHA Guideline for NSTE-ACS3

  • ACC/AHA/SCAI Guideline for PCI4

For Product Inquiries

Contact Medical Information:

To Speak with a Product Specialist

Contact Medical Information:


  • Known hypersensitivity to any component of AGGRASTAT

  • History of thrombocytopenia with prior exposure to AGGRASTAT

  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month

Warnings and Precautions

  • AGGRASTAT can cause serious bleeding. If bleeding cannot be controlled discontinue AGGRASTAT.

  • Thrombocytopenia: Discontinue AGGRASTAT and heparin

Adverse Reactions

  • Bleeding is the most commonly reported adverse reaction


  1. Valgimigli M et al. Eur Heart J 2010;31:35-49

  2. Mardikar HM et al. Am Heart J 2007;154:344e1-344e5

  3. Amsterdam EA et al. J Am Coll Cardiol 2014;64:2645-2687

  4. Levine GN et al. J Am Coll Cardiol 2011;58:e44-e122

Download Aggrastat Prescribing Information